JB
INZY

Julian Baker’s Inozyme Pharma INZY Stock Holding History

Julian Baker’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-106,999
Closed -$510K – 120
2022
Q2 		$510K Hold
106,999
– – ﹤0.01% 110
2022
Q1 		$438K Hold
106,999
– – ﹤0.01% 115
2021
Q4 		$730K Hold
106,999
– – ﹤0.01% 120
2021
Q3 		$1.24M Hold
106,999
– – 0.01% 115
2021
Q2 		$1.82M Hold
106,999
– – 0.01% 112
2021
Q1 		$2.12M Hold
106,999
– – 0.01% 114
2020
Q4 		$2.21M Sell
106,999
-11,501
-10% -$274K 0.01% 108
2020
Q3 		$3.12M Buy
+118,500
New +$2.94M 0.01% 92

Other funds holding INZY

SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Julian Baker's INZY Position: Q3 2022 in Review

Julian Baker sold out of Inozyme Pharma (INZY) in Q3 2022, closing a stake of 106,999 shares — an estimated $510K sold.

Julian Baker first reported a position in INZY in Q3 2020 and held it in 8 quarters. The position peaked at $3.12M in Q3 2020. 39 funds tracked by Wall St. Rank hold INZY as of Q3 2022.

  • Julian Baker reported no remaining Inozyme Pharma position as of Q3 2022 after selling out during the quarter.
  • Julian Baker sold 106,999 Inozyme Pharma shares in Q3 2022, an estimated $510K.
  • Julian Baker first reported a position in Inozyme Pharma in Q3 2020 and held it in 8 quarters.
  • Julian Baker's Inozyme Pharma position peaked at $3.12M in Q3 2020.
  • 39 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2022.

Based on Baker Bros. Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.